If we have learnt anything from the last two years, it’s that virus protection is not to be sniffed at Pharma innovation specialists, Poolbeg Pharma–a recent spin out from Open
Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss the in-licencing of a novel, first-in-class RNA-based immunotherapy for respiratory virus infections. Jeremy tells us more about this
Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
When it comes to individual equities as always there have been some notable laggards and a few surprise leaders. Here, we have selected a dozen “alternative” companies to follow for
If party season in the Square Mile looks set to be a washout again this year, at least its inhabitants of bankers, lawyers and accountants have plenty of work to
Artificial intelligence and the insights it can provide offer a route for infectious diseases to stay in the spotlight and draw interest from R&D investors worldwide. Liam Tremble at Poolbeg
Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss a new deal with AnaBio to develop an oral vaccine delivery platform. Jeremy talks us through the details
Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a
Poolbeg Pharma, which is focused on developing treatments for infectious diseases, has signed an option agreement to license MelioVac with University College Dublin (UCD). MelioVac is a vaccine for melioidosis,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
